Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Predictive biomarker discovery

PROMISE Trial

The PROMISE trial (PRedictability of Outcome based on iMmunological sIgnatureS in lung cancEr – an explorative investigation) is a collaborative exploratory biomarker study with clinical partners at the Thoraxklinik and UKHD, funded by the Dietmar-Hopp foundation. The trial focusses on the identification of predictive markers or signatures for response and resistance to current standard of care treatment in stage IV non-small cell lung cancer (NSCLC) patients. Biomaterials, such as tissue, serum, plasma, PBMCs, breath condensates and stool samples, are systematically collected longitudinally and will be analyzed by e.g. WGS/WES, PanelSeq, RNASeq, Nanostring, metagenomics, immunohistochemistry and virtual microscopy with semi-automated image analyses, multiplex Cytokine/Chemokine assays, mass spectrometry, RAMAN spectroscopy and flow cytometry.. Due to the advancement in high-throughput technologies, we incorporate heterogeneous data from multiple technologies to improve our understanding of the molecular dynamics associated with biological processes. Pipelines for multi-omics data analysis comprising MHC I/II epitope prediction and V(D)J enrichment immune profiling analysis have been set up. Further, we are developing machine- and deep learning approaches on an in-house generated graph database enabling us to extract relevant biological interpretations and to identify novel relationships by integrating high-dimensional data. For an in-depth understanding of the "individual disease" and for the identification of predictive biomarkers, an integrated analysis of the multiomics (Charoentong P et al, 2017, Cell Rep, 18(1):248-62) and wet lab data is performed.

NEOMUN Tial

The translational research program of the NEOMUN trial ("NEOadjuvant anti-PD-1 imMUNotherapy in resectable NSCLC: The NEOMUN Trial") is supported by NCT POC trial funding and is carried out in the CCU/NCT 3.0 TME Unit in collaboration with PD Dr. M. Eichhorn and colleagues (Surgery Department, Thoraxklinik Heidelberg). A major aim is the analysis of possible therapy-associated changes in different tumor regions (e.g. core vs. border), lymph nodes or healthy lung tissue and the potential identification of predictive markers.

IReP Trial

The IReP trial ("Immune Response Prediction" trial; funded by the Dietmar-Hopp Foundation) is an exploratory study evaluating the potential of immune signature profiling for predicting response to neoadjuvant chemoimmunotherapy in patients with resectable stage II/III non-squamous NSCLC. An in depth analysis of the tumor microenvironment and genomic alterations is performed in pre- and post-treatment tissue and data is correlated with response as defined by Major pathologic response. The trial is performed in collaboration with PD Dr. M. Eichhorn (Department of Surgery, Thoraxklinik).

Contact

Inka Zörnig, PhD - inka.zoernig@nct-heidelberg.de 

Pornpimol Charoentong, PhD - pornpimol.charoentong@nct-heidelberg.de 

Publications

Eichhorn F, Klotz LV, Kriegsmann M, Bischoff H, Schneider MA, Muley T, Kriegsmann K, Haberkorn U, Heussel CP, Savai R, Zoernig I, Jaeger D, Thomas M, Hoffmann H, Winter H, Eichhorn ME. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. Lung Cancer. 153:150-157 (2021). doi: 10.1016/j.lungcan.2021.01.018.

to top
powered by webEdition CMS